Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10326158 | 1.00 | TACR1 (0.39) | TACR1HSD17B2KMT2AALDH1A1HPGD | |
| SCHEMBL10326159 | 1.00 | TACR1 (0.39) | TACR1HSD17B2KMT2AALDH1A1HPGD | |
| SCHEMBL10327296 | 0.91 | HSD17B2 (0.44) | HSD17B2 | |
| SCHEMBL10326376 | 0.91 | HSD17B2 (0.44) | HSD17B2 | |
| SCHEMBL10326648 | 0.91 | HSD17B2 (0.44) | HSD17B2 | |
| SCHEMBL10326375 | 0.87 | HSD17B2 (0.47) | HSD17B2ALDH1A1 | |
| SCHEMBL10326714 | 0.87 | HSD17B2 (0.47) | HSD17B2ALDH1A1 | |
| SCHEMBL10326647 | 0.87 | HSD17B2 (0.47) | HSD17B2ALDH1A1 | |
| SCHEMBL10326157 | 0.85 | HSD17B2 (0.38) | HSD17B2KMT2A | |
| SCHEMBL10326368 | 0.85 | HSD17B2 (0.38) | HSD17B2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | TACR1 4141/4885HSD17B2 1447/4885KMT2A 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.